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Lomeguatrib, an O
6-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with
temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4
cutaneous or unknown primary melanoma metastases were treated with lomeguatrib 40mg, b.i.d. for 10 or 14 days and
temozolomide 75–100mgm
 2 on days 1–5. Drugs were administered orally with cycles repeated every 28 days, for up to six cycles.
A total of 32 patients were recruited to the study. Lomeguatrib for 10 days with temozolomide 75mgm
 2 was established as the
optimal extended lomeguatrib dosing schedule, with haematological toxicity being dose limiting. There were two partial responses to
treatment giving an overall response rate of 6.25%. Extending lomeguatrib administration beyond that of temozolomide requires a
reduced dose of the latter agent. Only limited clinical activity was seen, suggesting no advantage for this regimen over conventional
temozolomide administration in the treatment of melanoma.
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Treatment for metastatic melanoma is unsatisfactory: the standard
of care, dacarbazine, offers modest response rates and has never
been shown to improve patient survival compared with purely
supportive care. Despite these shortcomings and over 30 years of
randomised phase 3 trials no other agent, or combination of agents,
has supplanted dacarbazine (Atkins, 1997; Balch et al, 1997).
Much effort has been devoted to understanding the intrinsic and
acquired resistance of melanoma to chemotherapy. The most
commonly applied treatments, temozolomide and dacarbazine, are
methylating agents that share the active moiety methyltriazine-
imidazolecarboxamide. Their cytotoxicity is mediated principally
through methylation of DNA at the O
6 position of guanine (Ockey
et al, 1986; Margison and O’Connor, 1990; Kaina et al, 1997).
Repair of the lesion by O
6-methylguanine-DNA methyltransferase
(MGMT) and/or tolerance based on deficiencies in mismatch
repair or the engagement of apoptosis have been identified as
important aspects of resistance to dacarbazine and temozolomide
(Branch et al, 1993; Friedman et al, 1998). New molecules and
experimental approaches have followed but, as yet, none has
proved superior to single agent therapy.
Tumour cells frequently express high levels of MGMT, and
pre-clinical studies identify the protein as a key determinant of cell
survival (Chen et al, 1992; Kaina et al, 1997). Inactivation of
MGMT before dosing with an O
6-alkylating agent considerably
enhances the anti-tumour activity of the latter drug in vitro and in
animal tumour models (Dolan et al, 1990; Karran and Bignami,
1994; Friedman et al, 2002). We have previously reported the
development of lomeguatrib, a small molecule inactivator of
MGMT, and its use in combination with temozolomide. In a phase
1 trial we established lomeguatrib 40mg per day and temozo-
lomide 125mgm
 2 per day p.o. for 5 consecutive days as well
tolerated (Ranson et al, 2006). Total depletion of MGMT occurred
in three of five subcutaneous melanoma metastases analysed 4h
after the first dose of lomeguatrib, and 496% depletion was
observed in the other two.
A randomised phase 2 study failed to demonstrate any improved
efficacy for lomeguatrib/temozolomide, nor any responses in
patients treated with the combination after progression on
temozolomide alone (Ranson et al, 2007). Melanoma biopsies
taken in the 24–72h after patients finished their first cycle of
lomeguatrib and temozolomide showed residual MGMT activity.
The daily dose of lomeguatrib was increased to 80mg, which
remained well tolerated. It transpired that there was rapid recovery
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sof MGMT levels once dosing with lomeguatrib was completed,
allowing the repair of O
6-meG before the two rounds of DNA
replication required for cytotoxicity could occur. The pharmaco-
dynamic data suggested that the inactivator should be adminis-
tered for several days after temozolomide treatment, and the
current study was devised to determine the tolerability of the
chemotherapy regimen when given with 10 or 14 days of
lomeguatrib. The MGMT inactivator was given at 80mg per day
(40mg, b.i.d.) as this had been well tolerated with temozolomide in
the randomised phase 2 trial. In addition, tumour response rates,
pharmacodynamics (reported in the accompanying paper), time to
progression and survival were investigated.
PATIENTS AND METHODS
Inclusion and exclusion criteria
Patients with histologically proven cutaneous melanoma or
unknown primary melanoma with metastases were eligible for
the study, provided that they had not previously received systemic
chemotherapy for melanoma. Other requirements included stage
III or IV measurable disease, age 418 years, Eastern Cooperative
Oncology Group performance status of 0 or 1, life expectancy 412
weeks, adequate bone marrow and biochemical function (haemo-
globin 410g per100ml, white blood cells 43 10
9 per litre,
absolute neutrophil count 41.5 10
9 per litre, platelets4100000
per ml), creatinine p1.25 upper limit of normal (ULN), bilirubin
p1.25 ULN, AST p5 (metastases to liver) or 2 ULN.
Patients were excluded if within 4 weeks of radio- or
immunotherapy, pregnant or nursing, still recovering from
surgery, suffering from significant comorbidity, had known brain
metastases, had a history of seizures or were on anti-epileptic
medication.
The study was conducted in accordance with the principles of
the International Conference on Harmonisation of Good Clinical
Practice guidelines and the Declaration of Helsinki Principles. The
trial was approved by an independent ethics committee according
to national and local requirements at each trial centre. All patients
gave informed, written consent.
Study design and statistical considerations
The trial was a multi-centre, dose escalation study in which
approximately 40 patients were to be enrolled. The aim of the
study was to define the optimally tolerated dose of temozolomide
given for 5 days with lomeguatrib given for 10 or 14 days. If one of
three patients at a dose level developed dose-limiting toxicity, up
to three additional patients were treated at that dose level. If one of
the three additional patients developed a dose-limiting toxicity,
dose escalation ceased and six patients were treated at the
preceding dose level. This lower dose level was defined as the
maximum tolerated dose unless X2 of 6 patients developed dose-
limiting toxicity. Dose-limiting toxicity was defined as any of the
following events: grade 4 neutropaenia lasting 45 days or if
associated with infection/fever, grade 4 thrombocytopaenia for 45
days, grade 3 or 4 non-haematological toxicity (excluding grade 3
nausea and vomiting in patients who had not received optimal
treatment with anti-emetics) and drug-related death. Expansion at
the optimally tolerated dose was mandated to allow a preliminary
assessment of efficacy, toxicity, pharmacokinetic and pharmaco-
dynamic end points. A second expansion, to 80 patients, was
permitted should the effects of the optimally tolerated dose
warrant further study. The median time to progression and median
survival time were estimated using Kaplan–Meier survival curves.
Patients who had not progressed by the end of the study or who
withdrew before progression and patients who had not died were
censored for the respective analyses.
Treatment
Lomeguatrib enteric-coated 10mg capsules were obtained from
Kudos Pharmaceuticals (Cambridge, UK), and temozolomide was
purchased from Schering Plough Ltd (Welwyn Garden City, UK),
as 5, 20, 100 and 250mg capsules. Patients received lomeguatrib
40mg, b.i.d. (p.o.) for 10 or 14 consecutive days every 4 weeks for
up to six cycles. Temozolomide was administered on days 1–5 at
100mgm
 2 per day (p.o.) 2h after lomeguatrib, with a planned
escalation to 125mgm
 2 per day according to tolerability. Patients
fasted for 1 and 2h before and after temozolomide and
lomeguatrib respectively.
A treatment delay of up to 2 weeks was allowed for resolution of
drug-related toxicity. Dose reductions in temozolomide were
mandated in the event of grade 4 haematological toxicity,
grade 3 toxicity lasting 7 or more days or any grade 3 or 4
non-haematological toxicity. These were in decrements of 25 or
50mgm
 2 per day according to the type of toxicity encountered.
Patients could be withdrawn for excessive toxicity, progressive
disease, serious violation of the study drug protocol or withdrawal
of consent.
Evaluation of response and toxicity
All eligible patients who received any part of the treatment were
considered assessable for toxicity. Patients were assessed for
adverse events at each attendance. Physical exam, performance
status and vital signs were recorded at the beginning of each
treatment cycle. Complete blood count was checked before
treatment and on days 14, 21 and 28, with blood chemistry tested
on days 1, 14 and 28. Patients who developed grade 4 bone marrow
suppression were assessed every 1–2 days. Adverse events were
graded according to the National Cancer Institute-Common
Toxicity Criteria version 2.0. Tumour response was assessed every
second cycle based on clinical and radiological findings in
accordance with the RECIST criteria.
Pharmacodynamics
In a subset of patients peripheral blood mononuclear cell (PBMC)
samples were obtained before treatment, 4h after the first drug
dose and at the end of treatment (day 10 or 14 depending on
schedule) during cycle 1. Samples were assayed for MGMT activity,
and levels of O
6- and N7-methylguanine in DNA. Venous blood
(5–10ml) was collected into tubes containing 100ml 0.5 M EDTA
and stored on ice for maximum of 4h before isolation of PBMC
and analysis of MGMT (Watson and Margison, 2000).
RESULTS
A total of 32 patients were enrolled in the study between August
2005 and May 2006, with characteristics as summarised in Table 1.
All patients were evaluable for toxicity, but only 28 for efficacy.
Four patients did not complete two cycles of treatment: three due
to toxicity, one by choice.
Toxicity
Two patients died of causes other than melanoma while on
treatment. In one instance the cause of death was unable to be
ascertained by the study team, in the other the patient was
admitted with a neutropaenic fever. Melanoma in the patient had
progressed and the patient developed septic shock and multi-organ
failure, classified as probably and possibly related to treatment
respectively. A total of 86 cycles of treatment were administered,
with 46 having to be delayed and seven individuals needing dose
reductions. All the delays and dose adjustments were due to
haematological toxicity.
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sIn the first cohort, of 10 days lomeguatrib with temozolomide
100mgm
 2 per day, all three patients experienced significant
myelotoxicity and required dose reductions and delays in
treatment. Temozolomide 75mgm
 2 per day with 10 days
lomeguatrib was better tolerated. A third cohort, with lomeguatrib
dosing extended to 14 days was also recruited. Nine patients were
treated in this last cohort, which was twice expanded to further
assess feasibility beyond cycle 1 after proving just tolerable in the
terms described in the protocol. Three patients experienced grade
4 neutropaenia and/or neutropaenic fever in cycle 1, and all but
one required a delay in administering subsequent cycles. The
second cohort was therefore expanded to allow a more accurate
assessment of efficacy.
Although all patients had at least one treatment-emergent
adverse event, therapy was well tolerated aside from the increased
haematological toxicity noted in cohorts 1 and 3. All treatment-
related serious adverse events were neutropaenic episodes
associated with fever and/or infection. The most frequent non-
haematological toxicities attributed to treatment are summarised
in Table 2, and were in keeping with those described for
temozolomide alone.
Efficacy
Of the 32 patients treated, 28 were evaluable for response.
There were two partial responses to treatment, one each in cohorts
1 and 2, giving an overall response rate of 6.25%. A further 10
patients had stable disease, but in only 4 cases did this extend
beyond the second assessment at the end of cycle 4. Median time to
progression was 62 days, and median overall survival was 264 days.
In view of the lack of efficacy the second expansion phase of the
trial was not performed.
Pharmacodynamics
Peripheral blood mononuclear cell samples were obtained from 10
patients during the course of the study. These were analysed for
levels of DNA damage, specifically O
6- and N7-methylguanine, and
for MGMT expression. Detailed results are presented in the
accompanying paper.
DISCUSSION
Prolonged inactivation of MGMT in this patient group failed to
improve upon the activity expected from temozolomide alone.
The response rate of 6.25% with combination therapy is
disappointing, being approximately half that seen in the phase 3
comparison of temozolomide and dacarbazine and our earlier
phase 2 trial of lomeguatrib and temozolomide – trials with similar
entry criteria to the current study (Middleton et al, 2000; Ranson
et al, 2007). Results were very similar to those achievable with
Table 1 Patient characteristics by dose cohort
Cohort 1 2 3
Lomeguatrib dose 40mg, b.i.d., for 10 days 40mg, b.i.d., for 10 days 40mg, b.i.d., for 14 days
Temozolomide dose 100mgm
 2 per day 75mgm
 2 per day 75mgm
 2 per day
Number of patients 3 20 9
Median age (range) 70 (53, 81) 56 (35, 78) 51 (37, 71)
Gender (M/F) 3/0 12/8 3/6
Stage
30 2 1
M1a 0 1 3
M1b 2 5 0
M1c 1 12 5
Performance Status (0/1) 1/2 19/1 8/1
M¼male; F¼female.
Table 2 Most common treatment-related toxicities
a
All adverse events Grade 3/4 adverse events
Total Cohort 1 Cohort 2 Cohort 3
N¼32 (%) N¼32 (%) N¼3( % ) N¼20 (%) N¼9( % )
Thrombocytopaenia 18 (56) 11 (35) 3 (100) 10 (50) 4 (44)
Neutropaenia 19 (59) 17 (53) 3 (100) 7 (35) 1 (11)
Febrile neutropaenia 9 (28) 9 (28) 0 4 (20) 1 (11)
Anaemia 5 (16) 0
Nausea 20 (63) 1 (3) 0 1 (5) 0
Vomiting 10 (31) 2 (6) 0 2 (10) 0
Constipation 14 (44) 0
Diarrhoea 6 (19) 1 (3) 1 (33) 0 0
Fatigue 13 (41) 1 (3) 0 1 (5) 0
Cough 9 (28) 0
Anorexia 9 (28) 0
Headache 12 (38) 0
Dizziness 8 (25) 0
Treatment delayed 24 (75) 3 (100) 13 (65) 8 (89)
aAdverse events considered possibly, probably or highly probably related to treatment occurring in 15% or more patients in any study arm.
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stemozolomide alone: median progression free and overall survival
were 62 and 264 days, compared with 58 and 241 days in the phase
3 study.
From the point of view of toxicity, the patients fared as expected.
The combination of lomeguatrib and temozolomide was well
tolerated: although haematological toxicity was more frequent it
was readily managed. Non-haematological side effects were very
similar to those seen for the methylating agent alone, with nausea
and vomiting, constipation, headache and fatigue predominant
(Middleton et al, 2000).
The rationale for the current study came from the phase 2 trial
involving lomeguatrib and temozolomide, where we observed
recovery of tumour MGMT activity within 24h of completing
treatment (Ranson et al, 2007). In that trial the efficacy of
lomeguatrib and temozolomide was no better than that of the
cytotoxin alone. O
6-methylguanine is toxic only through replica-
tion and may be repaired effectively at any point beforehand, so
one possible explanation was that the recovery of tumour MGMT
levels occurred before successive rounds of replication could cause
cell death (Ollila et al, 1998).
As measured in PBMCs, extended dosing with lomeguatrib
successfully depleted MGMT for the duration of treatment, and
resulted in the persistence of DNA damage. There was an evident
impact on bone marrow progenitor cells, because continued
suppression of MGMT activity required a reduction in the dose of
temozolomide given over 5 days due to haematological toxicity.
Used alone a total of 1000gm
 2 temozolomide is deliverable, but
with 5 days lomeguatrib only 625mgm
 2 is possible. Extending
the lomeguatrib dosing to 10 days requires a further reduction to
375mgm
 2 temozolomide over the 5 days, and this dose is barely
tolerable with 14 days of the inactivator (Middleton et al, 2000;
Ranson et al, 2006, 2007).
Despite the effects of the MGMT inactivator on enhancing bone
marrow toxicity, we failed to see a similar effect on melanomas,
suggesting that tolerance of damage and/or failure of downstream
elements required for cytotoxicity have greater importance in
melanoma cells. It seems likely that other survival pathways
prevent increased DNA damage from killing melanoma cells. For
example, several defects in the apoptotic machinery have been
reported in melanoma, such as upregulation of bcl-2, or epigenetic
silencing of DAP kinase and Apaf-1. Another possible explanation
for the difference between tumour and bone marrow is that
tumour doubling times are such that the extension of MGMT
inactivation to 10 or 14 days is still not sufficient to allow the
two rounds of replication required for cell killing. Indeed in one
series of patients studied for consideration of pulmonary
metastasectomy, median tumour doubling time was 66.9 days
(Ollila et al, 1998).
Our results, and those of others using O
6-benzylguanine
(Gajewski et al, 2005), hold out little hope for MGMT inactivation
in the effective treatment of melanoma. Despite the wealth of pre-
clinical data to support MGMT’s role in determining the outcome
of methylating agent treatment in melanoma, evidence for the
protein’s importance in the clinic is inconclusive (Middleton et al,
1998; Ma et al, 2002; Middleton and Margison, 2003). More might
be achievable with better targeting of inactivation to tumour, but
such agents are not yet available clinically. It also remains to be
seen whether inactivation might offer a benefit in other tumour
types, such as glioblastoma, where temozolomide is an active agent
and the importance of MGMT in determining chemoresistance
has been established (Hegi et al, 2005). In conclusion, adminis-
tration of an extended schedule of lomeguatrib with temozolomide
confers no advantage over conventional temozolomide dosing in
melanoma.
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